Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Nittendorf – page 5

351 clinical trials in Nittendorf, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nittendorf at a glance
351
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

351 trials in Nittendorf

Open in trial search

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:BeOne Medicines I GmbH

Colon cancer

Recruiting

A study to evaluate the safety and effectiveness of darizmetinib hydrochloride in patients who have had liver surgery due to colon cancer metastases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Darizmetinib hydrochloride
  • Sponsor:HepaRegeniX GmbH

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab
  • Sponsor:AstraZeneca AB

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Nittendorf

What the registry says about research in the country

01 Cardiovascular Research

Innovative research focusing on heart failure prevention through combination therapy studies. The trials evaluate new treatment approaches combining baxdrostat with dapagliflozin to reduce cardiovascular mortality risk.

  • Heart Failure Prevention
  • Cardiovascular Death Risk Reduction
  • Combination Therapy Assessment

These studies aim to advance our understanding of preventive strategies in cardiology.

02 Gastroenterology Studies

Clinical research exploring the effectiveness of Menthacarin in treating functional gastrointestinal disorders. The studies focus on symptom management and quality of life improvements for patients.

  • Gastrointestinal Function
  • Gut Permeability Assessment
  • Treatment Satisfaction Analysis

This research aims to enhance therapeutic options for patients with digestive system disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.